Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -319.36% is 53% above its 5-year average of -676.81%, near the high end of its 5-year range (-3381.95%–100.00%).
65.69% above its 12-month average of -930.77%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
-319.36%
GROSS MARGIN AVG TTM
-930.77%
GROSS MARGIN AVG 3Y
-831.67%
GROSS MARGIN AVG 5Y
-676.81%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+65.69%
CURRENT VS 3Y AVG
+61.60%
CURRENT VS 5Y AVG
+52.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-871.77%
vs the sector median at left
Absci Corporation
Market Cap
$1.74B
Gross Margin
-319.36%
TTM Avg
-930.77%
3Y Avg
-831.67%
5Y Avg
-676.81%
Market Cap
$1.74B
Gross Margin
83.34%
TTM Avg
81.78%
3Y Avg
81.39%
5Y Avg
75.51%
Market Cap
$1.74B
Gross Margin
12.55%
TTM Avg
11.67%
3Y Avg
11.80%
5Y Avg
12.59%
Market Cap
$1.73B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$1.75B
Gross Margin
21.37%
TTM Avg
23.53%
3Y Avg
23.33%
5Y Avg
22.63%
Market Cap
$1.77B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.71B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.74B | -319.36% | -930.77% | -831.67% | -676.81% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 83.34% | 81.78% | 81.39% | 75.51% |
| Novocure Ltd (NVCR)vs › | $1.74B | 76.13% | 75.94% | 76.33% | 77.05% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 12.55% | 11.67% | 11.80% | 12.59% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | 76.47% | 79.35% | 79.86% | 39.87% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 21.37% | 23.53% | 23.33% | 22.63% |
| Personalis, Inc. (PSNL)vs › | $1.71B | 22.65% | 27.17% | 24.91% | 27.04% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | 100.00% | 100.00% | 100.00% | 100.00% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 49.52% | 50.81% | 52.12% | 52.25% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | 100.00% | -1291.39% | -620.70% | -620.70% |
Gross Margin
-319.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -1168.84% |
| 2025-12-31 | -335.08% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | -3349.92% |
| 2025-03-31 | -1287.96% |
| 2024-12-31 | -2452.93% |
| 2024-09-30 | -97.24% |
| 2024-06-30 | -1101.65% |
| 2024-03-31 | -1262.58% |
| 2023-12-31 | -3381.95% |
| 2023-09-30 | -1382.39% |
| 2023-06-30 | -259.73% |
| 2023-03-31 | -176.12% |
| 2022-12-31 | -130.31% |
| 2022-09-30 | -43.69% |
| 2022-06-30 | -213.47% |
| 2022-03-31 | -1740.90% |
| 2021-12-31 | -90.01% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | -1416.48% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -68.51% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
